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LIST OF ABBREVIATIONS 
 
ASCs Adipose-derived stem cells  
ACs Articular chondrocytes  
ACI Autologous Chondrocyte Implantation  
AMIC Autologous matrix-induced chondrogenesis 
BM Bone marrow  
BMPs Bone morphogenic proteins 
CRD Cartilage Repair Device 
CaP Calcium phosphates 
ECM Extracellular matrix  
FDA Food and Drug Administration  
hBMSCs Human bone marrow stromal cells 
HAp Hydroxyapatite  
MACI Matrix-induced Autologous Chondrocyte Implantation  
MSC Mesenchymal stem cell  
NCs Neuroectoderm-derived nasal chondrocytes  
OA Osteoarthritis  
OC Osteochondral  
OCD Osteochondral Defect  
OP Osteoporosis  
PEG Poly ethylene glycol  
PLGA Poly lactide-co-glycolide  
PCL Poly ε-caprolactone 
PGA Polyglycolic acid (or polyglycolide) 
PLA Polylactic acid (or polylactide) 
RFE Radio Frequency Energy  
SF Silk fibroin  
TGF-β Transforming growth factor-β  
β-TCP β-tricalcium phosphate 
 
 
Abstract  
 
The treatment/regeneration of bone and cartilage diseases or defects, whether induced by 
rheumatism, joint dysplasia, trauma, or surgery presents great challenges that have not been fully 
solved by the current therapies. In the last few years, tissue engineering and regenerative 
medicine have been proposing advanced tools and technologies for bone and cartilage tissue 
regeneration, and some of which have successfully reached the market. Beyond the source of 
cells, the creation of superior structures for replacing defective bone and cartilage requires strong 
research in biomechanical signaling and synthesis of advanced biomaterials to mimic human 
tissues at the most varied levels. Natural and synthetic polymers, bioresorbable inorganic 
materials, and composites have been investigated for its potential as scaffolding materials with 
enhanced mechanical and biological properties. Porous scaffolds, hydrogels, and fibers are the 
most commonly biomimetic structures used for bone and cartilage tissue engineering. Herein, the 
concepts and current treatment strategies for bone and cartilage repair, as well as biomimetic 
strategies for bone and cartilage tissue engineering are overviewed. A global review of the 
ongoing clinical trials and of the scaffolds commercially available for the repair of osteochondral 
tissue is also presented. 
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5.1 INTRODUCTION 
 
Osteoarthritis (OA) and Osteoporosis (OP) are among the most disabling degenerative diseases 
that may lead to severe complications affecting the neuromuscular system thus significantly 
impairing patients’ quality of life (1, 2). OA is the highest-ranking disease among the 
musculoskeletal diseases and contributes to approximately 50% of the disease burden in this 
group (3). Current clinical treatments for OA and OP involve non-steroidal anti-inflammatory 
drug administration and surgery such as osteotomy, abrasion arthroplasty, microfracture, and 
autologous and allogeneic cartilage tissue grafts, and autologous chondrocytes (4). These 
treatments are well established and effective for reducing the patients’ pain, but are not able to 
completely restore the patient’s mobility. Therefore, the demand for new therapeutic options for 
complete healing of bone, cartilage and octeochondral defects (OCDs) is significant. Bone and 
cartilage diseases or defects are directly related with joint degeneration. Such disorders can be 
caused by rheumatism, joint dysplasia and/or trauma and are particularly prevalent in countries 
with high life expectation. Articular cartilage damage can arise as a consequence of both acute 
and repetitive trauma resulting in pain, effusion and/or mechanical symptoms, affecting directly 
the individuals life style, as work, hobbies and daily tasks (5). Cartilage lesions in joints can have 
different degrees; superficial lesions, as fissures or cracks are classified as grade 1. A grade 2 
abnormality is defined when cartilage is affected up to 50% of its thickness while grade 3 lesions 
are characterized by defects in which more than 50% of the cartilage thickness, down to the 
subchondral bone but without bone penetration, is affected. The final grade is the commonly 
termed OCD (grade 4) that results from the cartilage damage with penetration into the 
subchondral bone. 
Although articular cartilage comprises just one type of cells, chondrocytes become less active 
with age and injury. Furthermore, the avascular nature of cartilage together with the declining 
function of chondrocytes leads to the inability of full-thickness defects to heal spontaneously. If 
untreated, these lesions can progress to more-serious degenerative joint conditions. Tissue 
engineering is a multidisciplinary field of research that employs principles of chemistry, biology, 
and engineering sciences towards growth, development and regeneration of damaged tissues or 
organs (6). It can involve the use of scaffolds combined with cells and suitable biochemical 
signals to design and create of-the-shelf organs and tissues substitutes. Despite the promise of 
tissue engineering, a better understanding of the composition, structure, and properties of bone 
and cartilage, can guide scientists to achieve the adequate tissue engineered grafts to ideally 
repair and regenerate bone and cartilage tissues. Bone and cartilage have a three-dimensional 
architecture with several levels of organization comprising micro- and nano-structures (Figure 
5.1) (7). Cancellous bone is a porous structure, whereas cortical bone is composed of osteons that 
consists of a concentric series of layers (lamellae) of mineralized collagen Type I matrix. 
Articular cartilage presents a stratified architecture, which consists of three zones where in the 
superficial zone collagen Type II fibres are oriented tangentially to the articular surface, in the 
transitional zone have no predominant orientation and become aligned perpendicularly to the 
calcified cartilage, anchored in subchondral bone in the deep zone. Articular cartilage has poor 
intrinsic ability for healing due to its isolation from vessels and nerve supply. On the other hand, 
bone is a vascular and innervated tissue. While bone is mineralized, normal cartilage tissue is not 
mineralized and is a highly hydrated tissue. 
 
 
(Insert Figure 1) 
 
 
Herein, cartilage and bone physiology and disorders are discussed in terms of currently applied 
treatments. Their limitations and the potential solutions proposed within tissue engineering and 
regenerative medicine field are presented. Applied or tested materials, cells, bioactive molecules 
and tissue engineered techniques are briefly described. To address the question ‘How close are 
we to bedside?’, the ongoing clinical trials and the related products that have already reach the 
market for osteochondral (OC) tissue regeneration are also reviewed.  
 
 
5.2 CONCEPTS AND TREATMENT STRATEGIES 
 
In order to understand what sort of bone and cartilage tissue engineering strategies could be best 
for repair/reconstruct defects, it is important first to recognize the structure, concepts and current 
therapeutic approaches targeting the different bone and cartilage lesions. 
 
5.2.1 Bone 
 
Bone is a complex, highly organized and specialized connective tissue with many functions. All 
bones have a mechanical function providing attachment to various muscle groups. In addition, in 
some parts of the body, bones provide a protective function to vital structures - skull (brain), ribs 
(lungs, heart) and pelvis (bladder, pelvic viscera). Some bones retain their hematopoietic 
function in adults - vertebrae, iliac crests, proximal parts of femur and humerus (3, 4). All bones 
serve as a reservoir of calcium and actively participate in the calcium homeostasis in the body. 
Bone is composed of cortical (compact) (80%) and trabecular (cancellous or spongy) (20%) 
tissues. Cortical bone tissue forms the outer shell, or cortex, of the bone and has a dense structure 
with a porosity of about 5-10% (3-5). It is the primary component of the long bones of the arm 
and leg and other bones, where its greater strength and rigidity are needed. Trabecular bone 
tissue typically occupies the interior region of bones and is composed of thin plates, or 
trabeculae, in a loose mesh structure with porosity of 50-90%. It is highly vascularized and 
frequently encloses the bone marrow (BM) with high proportions of mesenchymal and 
hematopoietic stem cells. Trabecular bone tissue has a higher surface area but is less dense and 
stiff, and weaker than cortical bone. 
Bone has the ability to remodel, by altering its size, shape and structure to meet the mechanical 
demands placed on it. Bone remodeling is a dynamic, lifelong process in which resorption is 
followed by formation, respectively involving the activity of osteoclasts and osteoblasts (6). 
During bone formation, also called osteogenesis, pre-osteogenic cells are stimulated to migrate 
through a provisional matrix, which in a therapeutic/regenerative approach could be represented 
by bone-graft substitutes or a blood clot (7). The migrating cells then start a differentiation 
process that results in the secretion of the new bone matrix.  
Bone defects are often associated to a disease state (e.g. OA, OP, osteomyelitis, and osteogenesis 
imperfect) and trauma related injuries resulting from primary tumor resection and orthopedic 
surgeries (e.g. total joint arthroplasty and implant fixation). In addition, spinal fractures, called 
vertebral compression fractures, are the most common fracture in patients with OP, affecting 
nearly 700,000 people each year, typically postmenopausal women. However, others fractures 
like fractures of the hip, wrist, and proximal humerus are commonly observed in patients with 
OP (8). 
Treatments used by orthopedic surgeons for the reconstruction and repair of bone defects and 
fractures are mainly internal fixation and bone allografts and autografts (9). Allografting 
involves the transplant of tissue from one individual to another with a different genotype but of 
the same species, carrying the risk of immunomediated rejection or transmission of infectious 
diseases. By its turn, autograft is a piece of tissue that is transplanted from one part of the body 
to another in the same individual. This procedure ensures the long-term survival of graft and 
subsequent successful reconstruction due to intrinsic features such as osteoconductivity and, 
histocompatibity. Autografting is thus considered the clinical gold standard method (8, 9). 
However, a number of complications including infection, vascular injuries, chronic donor site 
pain and morbidity have been reported with the using autografts (10). 
Other approaches, such as vascularised fibula autograft, Ilizarov bone transfer technique, and 
Masquelet technique, where autologous bone grafting alone is not recommended due to the risk 
of resorption, have been used particularly for long bone defects reconstruction (11-13). 
Nevertheless, these techniques are mainly limited to cancer patients which have OP and suffer 
from impaired wound healing. 
 
5.2.2 Cartilage 
 
Articular (hyaline) cartilage regeneration is a priority of orthopedic care because the clinical 
need is expanding with the aging population (mainly in developed countries). Articular cartilage 
enables the joints to tolerate shearing forces and absorb shock and loads up to 20 times the 
body's weight. As health care is evolving, people live longer and population ages. Moreover 
societies are increasingly more dynamic, competitive and physically more demanding. With time 
articular cartilage increasingly bears more prolonged and cumulative skeletal stresses and 
shearing forces, increasing the potential to the development of degenerative diseases of cartilage 
as OA. Worldwide estimates indicate that 9.6% of men and 18% of women ≥ 60 years have 
symptomatic OA last decade (2). Joint surface defects are ubiquitous, with reported prevalence 
of arthritis of about 31% in knees, 17% in hip and 7% in hands (10). In respect to prevalence of 
joint pain, 38% is incident in knees, 18% in the shoulders, 14% in hands and hip and 16% in 
lower back. 
While long-term research goals for cartilage regeneration focus on harnessing stem cell therapies 
alone or in combination with biodegradable materials, in the near term orthopedists choose from 
multiple treatment strategies to manage cartilage injuries. When injuries occur fracturing or 
damaging the tibia or knee, and the patient wants to continue to practice their normal lifestyle (or 
his physical activity in the case of sportsmen for example) is usually indicated surgical 
intervention (11). That type of surgery can be performed by arthroscopy, and at least from the 
standpoint of controlling pain, arthroscopic surgery has as main advantage a significant reduction 
of postoperative pain (12). Literature describes that the minor the peripheral tissue damage, the 
lower the nociceptive stimulus at the surgery site, which will be crucial for the patient to have 
less pain after surgery (13). Procedures such as the suprapatellar approach for nail insertion are 
seen as options to avoid late postoperative knee pain (14). This minimally invasive approach 
uses an easy entry point, promoting lesions only in the Hoffa’s body, which is usually removed 
during arthroscopy because it can be inflamed or damaged and to better visualize the knee also 
(15). 
Currently the methods for the treatment of cartilage defects (e.g. OA) include the 
insertion/transplantation of OC tissue, cells, scaffolds or growth factors (GFs), alone or in 
combination, or even the use of radio frequency energy (RFE) methods (16). Procedures that are 
normally used for treatment of small articular cartilage defects include also RFE, chondrocyte 
implantation and BM stimulation techniques as drilling, debridement or microfracture. In the 
case of large defects, scaffolds and mosaicplasty are commonly used in the treatment (Figure 
5.2) (17). Although current methods for articular cartilage defects are promising, no treatment 
has resulted in complete regeneration of the hyaline cartilage and the subchondral bone. 
 
(Insert Figure 2) 
 
 
 
Drilling procedure aims to pierce the underlying subchondral bone, thereby inducing bleeding at 
the defect site and allowing the formation of a blood clot which contains BM mesenchymal stem 
cells (MSCs) that will differentiate helping in cartilage regeneration (18). Drilling was described 
by Pridie and Gordon (19) and it is known to cause thermal necrosis of the subchondral bone, as 
well as to result in an uneven repair surface and for these reasons is not a favored method of 
treatment (18, 20). Debridement is the simple excision of the damaged cartilage and has been 
shown to improve symptoms for five years or more (21). Opinion is divided as to whether 
arthroscopic debridement has any place in the treatment of established degenerative disorders, as 
OA, although this debate does not apply to the treatment of localized symptomatic chondral 
defects. 
Microfracture, which is based on marrow-stimulation that creates fibrocartilage (as drilling and 
debridement) at the site of the procedure, with varied amounts of collagen Types I, II and III 
(20), was introduced by Steadman et al (22) 20 years ago, and is one of the most used methods 
for cartilage repair. This type of cartilage is less durable, less resilient and less able to withstand 
shearing forces than native articular cartilage, composed mainly by collagen Type II (Table 5.1). 
While this approach can have good results in smaller lesions, clinical studies reflect the lack of 
durability over a long-term follow-up. By its turn, treatment of OCD in the foot has also been 
considered a great challenge due to the different biomechanical features as interestingly reported 
elsewhere (23).  
 
TABLE 5.1 Types of collagen and associated genes and cartilages phenotypes outcomes 
Type Outcome Gene(s) Disorders 
I Fibrocartilage 
COL1A1, 
COL1A2 
Osteogenesis 
imperfecta 
II 
Hyaline cartilage, 
makes up 50% of all 
cartilage protein 
COL2A1 
Collagenopathy, 
Types II and XI 
X 
Hypertrophic and 
mineralizing cartilage 
COL10A1 
Schmid metaphyseal 
dysplasia 
XI Cartilage 
COL11A1, 
COL11A2 
Collagenopathy, 
Types II and XI 
 
Mosaicplasty, or OC cylinder transplantation, was first described in 1993 (24). In this procedure, 
OC plugs are taken with a cylindrical cutting device and used to fill an articular cartilage defect. 
Advantages of this technique are on one hand the immediate filling of the deffects with mature, 
hyaline articular cartilage and on the other the simultaneous treatment of both chondral and 
OCDs. However, donor site morbidity is a concern and Hangody and Fules (25) recommend the 
limiting of the area to be treated to 1 to 4 cm
2
. There are also technical difficulties in restoring 
the surfaces of both cartilage and bone to produce a smooth, convex joint surface. The thickness 
of the donor cartilage may differ from that of the area to be treated and the reconstitution of the 
important subchondral layer may not occur. In addition, lateral integration rarely occurs (26) 
raising the concern that synovial fluid may penetrate through the subchondral layer possibly 
causing cyst formation. 
Autologous chondrocyte implantation (ACI) can result in more hyaline-like cartilage within the 
treated defect. The technique of ACI was first performed by Peterson et al (27) in Gothenburg in 
1987 and it was the first application of cell engineering in orthopedic surgery. In ACI, healthy 
cartilage cells are harvested, cultured and then re-implanted into the defect under a patch, in a 
second-stage surgery. Brittberg et al (28) presented the results of 23 patients with a mean follow-
up of 39 months. Good or excellent clinical results were reported in 70% of cases (88% of 
femoral condylar defects). Of the biopsies from treated femoral condylar lesions, 11 of 15 had a 
hyaline-like appearance. A more recent publication from the same group showed durable results 
up to 11 years following the treatment of OC lesions (29). 
Current drawbacks to this procedure are hypertrophy of the patch that can lead to further surgery 
and unreliable biological potential of the re-implanted cartilage cells. Furthermore, histological 
analysis apparently show that ACI is capable of producing hyaline-like tissue in some specimens, 
however the best repaired tissue is not morphologically or histochemically identical to normal 
hyaline cartilage, and fibrocartilage can be found frequently. 
A variation of the ACI technique using culture-expanded BM stromal cells has the advantage of 
not requiring an additional arthroscopic procedure in order to harvest articular cartilage (30). 
All of these techniques encounter limited success due to issues which include fibrocartilage 
formation, chondrocyte de-differentiation, and lack of tissue integration and mechanical support. 
 
 
5.3 BIOMATERIALS FOR BONE AND CARTILAGE REGENERATION 
 
The rationale of using biomaterials as scaffolds in tissue regeneration is to obtain a temporary 
three-dimensional structure for the in vitro growth of living cells and its subsequent implantation 
into the lesion area followed by its biodegradation as newly tissue is being formed. Several 
natural and synthetic polymers, bioactive inorganic materials, and their combinations have been 
employed for bone and cartilage tissue engineering and regeneration. Polymers have great 
stiffness and mechanical strength, and natural polymers add advantages such as their 
resemblance with the extracellular matrix (ECM), specific degradation rates due to the 
susceptibility to the action of enzymes, and improved recognition by the living body. Bioactive 
inorganic materials, such as calcium phosphates (CaP) and bioactive glasses, have good 
biocompatibility, osteoconductivity, and bioresorbability. Despite, they present poor mechanical 
properties that hinder its use in load-bearing applications. The combination of these different 
types of materials result in composite structures with significantly enhanced mechanical and 
biological properties for bone tissue engineering. In opposition, cartilage tissue is engineered 
using natural/synthetic polymers. 
The most promising polymers, inorganic materials and composites and their properties are 
briefly described as follows. 
 
4.3.1 Polymers 
 
Natural polymers, also known as biopolymers, have been extensively used owing their ability to 
interact with cells and to be susceptible to enzymatic degradation providing space for tissue 
ingrowth (31). Naturally occurring polymers most widely explores for bone and cartilage 
repair/regeneration are: i) proteins (e.g. silk fibroin (SF), collagen and gelatin); ii) 
polysaccharides (e.g. chitosan, alginate, gellan gum and derivatives); and iii) 
glycosaminoglycans (e.g. hyaluronic acid) (31). 
In comparison to biopolymers, synthetic polymers have several advantages; excellent processing 
characteristics, excellent mechanical and physical properties (e.g. elastic modulus, strength, and 
degradation rates), and bioresorbability (32). However, many of these polymers present several 
disadvantages, such as the possibility of causing persistent inflammatory reactions and not being 
capable to integrate with host tissues (33). The most used polymers are polyglycolic acid (or 
polyglycolide - PGA), polylactic acid (or polylactide - PLA), poly lactide-co-glycolide (PLGA), 
poly (D,L- lactic acid) (PDLLA), poly ethylene glycol (PEG), and poly ε-caprolactone (PCL). 
These polymers have received special attention since they can be self-reinforced to gain better 
strength properties (34). 
 
4.3.2 Bioactive inorganic materials 
 
Inorganic materials often used for bone repair and regeneration are CaP, namely hydroxyapatite 
(Ca5(PO4)3OH, HAp) and β-tricalcium phosphate (Ca3(PO4)2, β-TCP), bioactive glasses, and 
glass-ceramics owing their bioactivity, biocompatibility and osteoconductivity (35, 36). 
HAp is crystalline and is the most stable and least soluble CaP in an aqueous solution down to a 
pH of 4.2 (36). Aqueous precipitation (37, 38), hydrothermal synthesis (39), solid-state reaction 
using calcium oxide, calcium hydroxide or calcium carbonate, and hydrolysis of other CaP, have 
been methods used to prepare HAp. The detailed information on HAp synthesis and preparation 
is well established (40). β-TCP is a high temperature phase of CaP, which can only be obtained 
by its thermal decomposition at temperatures above 800ºC. β-TCP is biodegradable and has been 
extensively used as bone substitute, either as granules or blocks, or even in CaP bone cements 
(41). The resorption capability of HAp and β-TCP is different though their similarity in terms of 
chemical composition. It is believed that HAp has a slow resorption rate (1 to 2% per year) and 
may be integrated into the regenerated bone tissue, while β-TCP is completely reabsorbed (42, 
43). Therefore, clinical applications have been performed by combining HAp with β-TCP, which 
forms the biphasic CaP, improving the bioresorbability and strength of the bone substitutes (35, 
40, 44). Nevertheless, these materials are limited to non-load bearing applications due to their 
poor mechanical properties. 
Bioactive glasses and glass-ceramics have been used in bone regeneration due to their capability 
to react with physiological fluids thus bonding with bone through the formation of HAp layers at 
the implant interface thus stimulating bone growth (45, 46). These type of materials are 
osteogenetic and osteoconductive, while CaP exhibit only osteoconductive properties (41). It has 
also been found that reactions on bioactive glass surfaces release concentrations of Si, Ca, P and 
Na ions, thus inducing intracellular and extracellular responses (47). They are also able to 
improve osteoblast adhesion, vascularization in vivo, enzymatic activity, and differentiation of 
MSCs (48). In addition, glasses have shown great potential as reinforcing materials since they 
fully degrade in aqueous media (49, 50). Bioactive glasses are brittle materials; this limitation 
can be solved by the development of glass-ceramics or by the combination with an additional 
phase as a polymer, forming a composite (51, 52). There are different compositions of bioactive 
glasses, based on silicate, phosphate, and borate, which can be obtained through melt-quenching 
(53) and sol-gel process (54).  The most widely investigated bioactive glass for biomedical 
applications is the silicate-based glass designated 45S5, also known by its commercial name 
Bioglass
®
 (55). These types of glasses have higher chemical durability and durability limits as 
compared to others bioactive glasses (56). By its turn, phosphate-based glasses have unique 
dissolution properties in aqueous fluids, while borate-based bioactive glasses have faster 
degradation rates and are able to completely convert into apatite (57, 58). 
Bioactive inorganic materials can be doped with trace elements (e.g. strontium, zinc, magnesium, 
manganese, silicon), which can influence bone health and enhance biocompatibility, while 
strengthening the mechanical properties of the implants (59). Besides, minerals and traces of 
metal elements may provide physicochemical modifications in the produced materials, which can 
accelerate bone formation and resorption in vivo (60, 61). 
 
4.3.3 Composites 
 
Composite materials embracing a natural/synthetic polymeric matrix and bioactive inorganic 
materials, as fillers, appeared as a strategy to mimic the human bone, which is a three-
dimensional composite composed of organic, inorganic and cellular phases, strictly assembled to 
form the natural bone tissue. Composites are the combination of two or more materials, with 
different compositions and properties, resulting in a single structure with significantly improved 
mechanical and biological properties. Special interest has been attributed to nanocomposites for 
bone tissue engineering and regeneration due to the nanosized features of the fillers which can 
intensely improve the tissue bonding capacity of the polymeric matrices, that the individual 
materials cannot attain thus allowing the production of better biomaterials (7). The nanoparticles 
have large surface area when compared to the conventional micro-sized fillers, thus offering 
improved mechanical properties, while maintaining the osteoconductivity and biocompatibility 
of the fillers, as well as, cell adhesion and differentiation (62). 
Many combinations of polymers and inorganic materials have been proposed for the production 
of nanocomposites which final properties will be dependent. As aforementioned, the most 
common polymers used are of natural origin (collagen, gelatin, silk, chitosan, alginate, 
hyaluronic acid, and gellan gum) (63-69). By its turn, some synthetic polymers (e.g. PEG, PLA, 
PGA, PLGA, and PCL) have been also used and applied in the clinics. On the other side, 
nanosized fillers include nanoparticles of CaPs and bioactive glasses, carbon nanotubes, 
nanofibers, and nanoplatelets. These nanoparticles have been prepared through different 
processes, namely wet chemical precipitation (38), sol-gel synthesis (70), hydrothermal synthesis 
(71), mechanochemical synthesis (72), microwave processing (73), spray drying methods (74), 
and electrospinning (75), while nanocomposites have been prepared by simple mechanical 
mixing or co-precipitation. 
Further details on nanomaterials processing techniques and applications in bone tissue 
regeneration can be found elsewhere (76). 
  
4.4 BONE AND CARTILAGE TISSUE ENGINEERING 
 
Biomimetic strategies to develop new bone and cartilage tissue engineered constructs rely on 
bioactive structures able to mimic the natural tissue ECM in order to promote cell adhesion, 
migration, growth and matrix deposition forming a tissue-like substitute. These structures 
embrace three-dimensional porous and fibrous scaffolds, and hydrogels, with specific design, 
controlled degradation rate, mechanical properties, and porosity for efficient gases, nutrients, and 
regulatory factors transport. 
 
 
4.4.1 Bone tissue engineering 
 
Bone tissue engineering focuses on alternative treatment strategies to reduce the shortcomings of 
the current clinical treatments (i.e. infection, vascular injuries, immune rejection, chronic donor 
site pain and morbidity) by using the combination of materials science, engineering principles, 
and cell biology. Hence, the fabrication of composite constructs hierarchically structured from 
nano- to macro-size ranges inspired by the nature of bone, has been followed (77). 
Conventional technologies, such as foam replica method (78), solvent casting and particulate-
leaching (79), freeze-drying (80), phase separation (81), and gas foaming (82), often 
inexpensive, simple and flexible to optimize physico-chemical properties, have been used to 
fabricate scaffolds. Rapid prototyping (83) and electrospinning (84) are sophisticated techniques 
for the production of respectively, 3D structures and fibers, that allow the possibility of 
incorporating pharmaceutical agents. Molecular self-assembly is another strategy available for 
the production of nanofibers by creating supramolecular architectures (85). 
Several studies have been reporting the development of porous structures for bone tissue 
engineering using diverse materials and techniques (65, 78, 86-88). For example, Oliveira et al 
(78) developed macroporous HAp scaffolds with controlled morphology using the sponge replica 
method. The structures showed a porosity of ~70%, and highly interconnected macropores with a 
diameter in the range of 50–600 µm (Figure 5.3). Later, Barbani et al (86) produced a 
gelatin/HAp nanocomposite scaffold with elastic modulus similar to natural bone, using freeze-
drying technique. It was shown that HAp scaffolds supported the adhesion and proliferation of 
human MSCs onto the scaffolds. 
 
 
(Insert Figure 3) 
 
 
 
Yan et al (87) prepared a composite scaffold of SF and nanosized CaP combining solvent casting 
and freeze-drying methods that allowed the formation of a homogeneous macroporosity and 
porosity distribution (Figure 5.4). The scaffolds are also characterized by the good mechanical 
properties and stability, and self-mineralization capability which represent a major feature for 
bone tissue engineering. 
 
(Insert Figure 4) 
 
 
 
Eftekhari et al (89) developed a novel porous scaffold composed of cotton-sourced cellulose 
microcrystals, HAp nanoparticles and PLLA with enhanced mechanical strength for bone tissue 
regeneration. A different preparation method, by applying cryogelation method as an alternative 
to freeze-drying, was used to prepared collagen/nano-HAp scaffolds for bone regeneration (90). 
The scaffolds showed improved mechanical properties and allowed high cells proliferation. 
Hydrogels have been also explored in the context of bone tissue engineering due to their 
structural and compositional similarities with the ECM that allow efficient mass transfer as well 
as the encapsulation of cells and biomolecules (91). These structures comprise a hydrophilic 
porous network that can be controlled by solvent casting and particulate leaching, phase 
separation, gas foaming, solvent evaporation, freeze-drying, and blending with non-cross-
linkable linear polymers (92). Hydrogel networks can be engineered, into different sizes and 
shapes, as thin films, sheets, spheres, rods, hollow tubes, and bellows, due to their unique 
physical properties (93). Excellent reviews regarding a deep description of hydrogels properties 
were recently reported (94). 
Hydrogels have been produced combining synthetic or/and biopolymers and inorganic 
biomaterials, with desired physical properties, reproducibility, and biological activity for use in 
bone tissue engineering. For example, Gaharwar et al (95) developed hydrogels incorporating 
PEG and HAp presenting highly porous structures and interconnected porous structure with pore 
sizes of 100−300 nm (Figure 5.5). The results also showed osteoblast cell adhesion and bioactive 
attachment sites for the osteoblastic cells. An injectable and thermo-sensitive PEG-PCL-PEG 
copolymer, collagen, and nanosized HAp hydrogel for guided bone regeneration was developed 
by Fu et al (96). The results revealed good biocompatibility, biodegradability and new bone 
tissue formation after implanting the structures in rats. Gantar et al (97) developed bioactive 
glass-reinforced gellan-gum hydrogels with an open and well-interconnected porosity of about 
80% and a pore size of ~100-200 µm. 
 
(Insert Figure 5) 
 
 
 
Fiber-based scaffolds for bone tissue engineering are another good option to mimic the fibrous 
structure of ECM. Likewise, nanoscale fibrous scaffolds with similarities with the network of 
collagen fibrils of native ECM have received particular interest to enhance cell adhesion, 
proliferation and differentiation (98). Electrospun fibers have been explored as scaffolds similar 
to natural ECM to engineer and repair the bone tissue. Rajzer et al (99) prepared composite 
fibrous scaffolds with electrospun PCL and gelatin/CaP fibers with diameter in the range of 2-6.5 
µm and porosities of 74.3 ± 7.0% and 86.7 ± 2.3%, respectively for the gelatin side and for the 
PCL side of composite scaffold (Figure 5.6). In vitro tests proved the bioactivity of the scaffolds 
by the higher activity of ALP. Chae et al (84) fabricated alginate/HAp fibrous scaffolds via 
electrospinning, composed of random nanofibers holding homogeneously distributed HAp 
nanocrystals. 
 
(Insert Figure 6) 
 
 
 
5.4.2 Cartilage tissue engineering 
 
The limited ability of articular cartilage to regenerate has prompted the development of cell-
based tissue engineering techniques, such as ACI. However, the complexity of ACI and 
contraindications in wider clinical applications has driven the development of matrix-assisted 
chondrocyte implantation, which uses scaffolds to provide mechanical stability and to support 
chondrogenesis. Laboratory and clinical studies have examined the management of larger lesions 
using tissue-engineered cartilage (100). To improve neotissue formation, cells can be cultured 
in vitro in 3D matrices with exogenous stimuli, such as GFs, to promote graft maturation and 
biomechanical integrity. 
In order to outperform the currently used methods for treatment of grade 4 defects (penetration 
of the subchondral bone), novel tissue engineering approaches propose addressing OC 
regeneration by means of using bilayered scaffolds in combination with stem cells. That 
approach has in account the use of structures with two layers with different physical properties, 
usually a bioactive layer with a ceramic phase for the bony part, and a non-bioactive layer, 
composed by polysaccharides or proteins, or even biodegradable synthetic polymers for the 
cartilage-like layer (33, 101). 
OC tissue is mainly composed by osteoblasts and chondrocytes. The two neighboring, but 
different cell lines have extremely different in vivo physiologic conditions, which have to be 
understood and replicated in vitro to obtain improvements in OC tissue regeneration. 
Osteoblasts and chondrocytes are mononucleated cells that are derived from MSCs by GFs, via 
different signaling transcription pathways. Those factors can exhibit different and often opposite 
effects in the modulation of cells metabolism depending on their maturation stage and 
phenotype. Many adult tissues contain cell niches that in response to injury, for example, provide 
stem cells that are able to differentiate into multiple cell linages, including chondrocytes. The 
adult stem cells have gained significant attention over the past decade and became frontline 
management for cartilage defects in the very recent past. BM is one of the main cell niches used 
to this ends, presenting good potential and results (102-104). However there are more MSCs 
niches with potential to be used for cartilage and bone differentiation (105), as umbilical cord- 
and adipose-derived stem cells (ASCs). In the case of ASCs, Hoffa’s body is recently being 
explored as an interesting autologous source of cells to regenerate cartilage in knee-associated 
disorders (106, 107). Hoffa’s body, which is a fat pad of ASCs, has to be removed during an 
arthroscopy to facilitate the visualization of the knee and surgery handling, and also to avoid 
tissue inflammation as was explained before. This way, this tissue can be considered too as a 
promising source of ASCs with great potential to differentiate into chondrocytes and osteoblasts 
(108). Recently, also strategies using endothelial cells in co-culture with osteoblasts or stem cells 
are being used to promote vascularization in bony part (109, 110). 
To promote stem cell differentiation, GFs can be introduced in scaffolds in order to induce a 
faster host tissue response to the implanted matrix of material. In vitro osteogenic differentiation 
of ASCs could be induced by dexamethasone, L-ascorbic acid-2-phosphate, β-glycerophosphate, 
bone morphogenic proteins (BMPs), fibroblast growth factor (FGF), platelet-derived GF and 
transforming growth factor-β (TGF-β) (111, 112). Chondrogenic differentiation of ASCs 
requires GFs such as members of the TGF-β and BMPs families. 
Steinwachs et al (113) reported the technique of autologous matrix-induced chondrogenesis 
(AMIC).  AMIC involves the joint use of the Chondro-Gide (Geistlich Biomaterials, Wolhausen, 
Germany) collagen Type I / III membrane as a scaffold over a defect treated by microfracture. 
Short-term results were encouraging, however, long-term follow-up data is needed to 
substantiate preliminary findings (114). A novel approach to enhance cartilage repair with AMIC 
is to deliver GFs that selectively recruit and stimulate MSCs from the subchondral BM to invade 
cell-free scaffolds. Such GFs can be tailored also to activate chondrocytes in the surrounding 
healthy tissue to help filling the cartilage defect remodeling the tissue. 
Matrix-assisted chondrocyte implantation (MACI) (Genzyme, Oxford, United Kingdom) is a 
later surgical technique of cartilage repair and is a third generation variant of conventional ACI. 
Instead of injecting cultured chondrocytes underneath a periosteal or collagen Type I / III cover, 
the cells are pre-loaded onto a commercially-produced porcine collagen patch. At the second 
stage of the operation, the patch is manually cut to cover the dimensions of the cartilage defect 
and held in place with tissue glue and, where necessary, sutures. Currently there is a limited data 
on the mid- to long-term follow-up success of such a technique. 
Recently a new promising cell niche for articular cartilage regeneration was investigated by 
Pelttari et al (115). The authors showed that adult human neuroectoderm-derived nasal 
chondrocytes (NCs) can be constitutively distinguished from mesoderm-derived articular 
chondrocytes (ACs) by lack of expression of specific HOX genes, including HOXC4 and 
HOXD8. In contrast to ACs, serially cloned NCs could be continuously reverted from 
differentiated to dedifferentiated states, conserving the ability to form cartilage tissue in vitro and 
in vivo. NCs could also be reprogrammed to stably express HOX genes, typical of ACs, upon 
implantation into goat articular cartilage defects, directly contributing to cartilage regeneration. 
The effect of the scaffolds pore size was studied by Zhang et al (116) using porcine Type I 
collagen scaffolds applied for cartilage regeneration. The results obtained could help to establish 
the ideal conditions for future strategies for one of the most promising targets of regenerative 
medicine, the OC regeneration. The collagen porous scaffolds were prepared by means of using 
pre-prepared ice particulates that had diameters of 150–250, 250–355, 355–425 and 425–500 
µm. The collagen porous scaffolds prepared with ice particulates 150–250 µm in size best 
promoted the expression and production of Type II collagen and aggrecan (116). 
Adachi et al (117) evaluated the implantation of tissue engineered cartilage-like tissue composed 
by autologous chondrocytes cultured in atelocollagen gel for the treatment for full-thickness 
cartilage defects of the knee. Arthroscopic analysis was performed 2 years after implantation. 
According to the International Cartilage Repair Society scale, in 64 of 73 knees (87.7%) the 
implanted constructs were graded normal or nearly normal. The authors concluded that the 
procedure can be suggested for repairing full-thickness cartilage defect of the knee (117). 
Lu et al (118) used a baculovirus system that exploited FLPo/Frt-mediated transgene 
recombination and episomal mini-circle formation to genetically engineer rabbit ASCs. The 
baculovirus system conferred prolonged and robust TGF-β3/BMP-6 expression in rASCs 
cultured in porous scaffolds, which critically augmented rASCs chondrogenesis and suppressed 
osteogenesis/hypertrophy. Twelve weeks after implantation into full-thickness articular cartilage 
defects in rabbits, these engineered constructs displayed cartilage-specific zonal structures 
without signs of hypertrophy and degeneration, and eventually integrated with host cartilage 
(118). Wang et al (119) investigated the repair of articular cartilage defects with tissue-
engineered cartilage constructed by acellular cartilage matrices from the rabbit ear and seeded 
with ASCs. After in vitro chondrogenic differentiation for 2 weeks, the constructs were 
implanted in 4mm cartilage defects in rabbits. Articular cartilage defects of the rabbits implanted 
with tissue engineered constructs were filled with chondrocyte-like tissue with smooth surface, 
while in the group implanted with acellular scaffolds, the defect was filled with fibrous tissue 
(119). Forming a stable interface between the subchondral bone and tissue engineered cartilage 
components remains a major challenge. Dua et al (120) investigated the utility of HAp 
nanoparticles to promote controlled bone-growth across the bone-cartilage interface in an in vitro 
engineered tissue model system using BM derived stromal cells. Samples incorporated with HAp 
demonstrated significantly higher interfacial shear strength (at the junction between engineered 
cartilage and engineered bone) compared with the constructs without HAp, after 28 days of 
culture. 
 
5.5 CLINICAL TRIALS 
 
Significant strategies for regenerative medicine appeal to the use of cell therapy or tissue 
engineering, the first apply the effect of cell signaling for clinical application, the last approach 
combine scaffolds with bioactive signaling molecules and cells for tissue repair and regeneration. 
Among bioactive molecules, recombinant bone morphogenetic proteins (BMPs) growth factors 
are the most common used for bone growth and healing due to their osteoinduction ability. 
Nevertheless, some complications relating to the off-label use of BMP-2 in spinal and trauma 
surgery have been reported to result in the formation of ectopic epidural bone associated with 
severe neurological impairment in anterior interbody fusion surgery (121, 122). 
Different stem cell sources as, human MSCs, human BM stromal cells (hBMSCs), and human 
endometrial stem cells have been proposed for bone regeneration. It was reported a clinical trial 
in which autologous BMSCs were seeded in macroporous HAp scaffolds showing a promising 
outcome of functional bone recovery, with good implant integration and host bone formation 
during 6 to 7 years post-surgery (123). Other ongoing and complete clinical trials using several 
tissue engineering strategies for bone and cartilage repair/regeneration are well reported (124-
126). There is a variety of bone scaffolding products currently available in the market for clinical 
utility. On the contrary, few scaffolds are being commercialized for OC regeneration. This fact 
reflects the great challenge when addressing the simultaneous regeneration of two distinct tissues 
such as bone and cartilage. Considering all bone and cartilage tissue engineering and 
regenerative medicine strategies for clinical application, ongoing and completed clinical trials 
(with no reported results yet) for OC repair/regeneration using scaffolds or cell therapies, or even 
scaffolds combined with cells pre-cultures in vitro are summarized in Table 5.2. 
 
TABLE 5.2 Overview of ongoing and complete clinical trials using strategies for OC regeneration. 
Information obtained from https://clinicaltrials.gov/. 
NCT number 
Date and 
phase 
Name of the clinical 
trial 
Patients 
age 
Follow-
up 
Procedure 
NCT00891501 
2006-2014 
 
Phase 2 and 3 
The Use of Autologous 
BM MSCs in the 
Treatment of Articular 
Cartilage Defects 
15-55 yrs n.d. 
BM MSCs 
aspiration and 
implantation 
NCT00560664 
2007-2013 
 
Phase 3 
Comparison of ACI 
Versus Mosaicoplasty 
18-50 yrs 24 mths 
Autologous 
chondrocytes 
transplantation 
and 
mosaicoplasty 
 
NCT00945399 
2008-2011 
 
Comparison of 
Microfracture Treatment 
and CARTIPATCH® 
Chondrocyte Graft 
Treatment in Femoral 
18-45 yrs 18 mths 
ACI and 
microfracture 
Phase 3 Condyle Lesions 
NCT00793104 
2008-2012 
 
Phase 3 
Evaluation of the CR 
Plug (Allograft) for the 
Treatment of a Cartilage 
Injury in the Knee 
≥ 18 yrs 24 mths 
Placement of 
allograft CR 
Plug in primary 
injury site 
NCT00821873 
2008-2012 
 
Phase 3 
Evaluation of the CR 
Plug for Repair of 
Defects Created at the 
Harvest Site From an 
Autograft in the Knee 
 
18-55 yrs 24 mths 
CR Plug 
implantation in 
the harvest site 
NCT01409447 2009-2011 Repair of Articular OCD 18-60 yrs 12 mths 
Biphasic OC 
composite 
implantation 
NCT00984594 
2009-2012 
 
Phase 3 
Evaluation of a 
Composite Cancellous 
and Demineralized Bone 
Plug (CR-Plug) for 
Repair of Knee OCDs 
18-55 yrs 24 mths 
Autograft 
implantation in 
the primary 
defect site; CR-
Plug 
implantation in 
the harvest site 
NCT01183637 
2010-2014 
 
Phase 2 
Evaluation of an 
Acellular OC Graft for 
Cartilage Lesions 
≥ 21 yrs 24 mths Microfacture 
NCT01159899 
2010-2014 
 
Phase 0 
Transplantation of BM 
Stem Cells Stimulated by 
Proteins Scaffold to Heal 
Defects Articular 
Cartilage of the Knee 
30-75 yrs 12 mths 
Transplantation 
of BM stem 
cells activated in 
knee arthrosis 
NCT01209390 2010-2016 
A Prospective, Post-
marketing Registry on the 
Use of ChondroMimetic 
for the Repair of OCDs 
18-65 Yrs 
 
36 mths 
 
Chondromimetic 
 
NCT01473199 2011 
BioPoly RS Knee 
Registry Study for 
Cartilage Defect 
≥ 21 yrs 5 yrs 
BioPoly RS 
partial 
resurfacing knee 
Replacement implantation 
NCT01290991 2011-2012 
A Study to Evaluate the 
Safety of Augment™ 
Bone Graft 
18-40 yrs 12 mths 
Augment Bone 
Graft 
NCT01410136 2011-2014 
Chondrofix OC Allograft 
Prospective Study 
18-70 yrs 24 mths 
Allogeneic OC 
grafting 
NCT01477008 
2011-2014 
 
Phase 3 
BiPhasic Cartilage Repair 
Implant 
Up to 54 
yrs 
12 mths 
Marrow 
Stimulation 
NCT01282034 
2011-2015 
 
Phase 4 
Study for the Treatment 
of Knee Chondral andOC 
Lesions 
18-60 yrs 24 mths 
Marrow 
stimulation - 
Drilling or 
Microfractures 
 
NCT01471236 
2011-2017 
 
Phase 4 
Evaluation of the Agili-C 
Biphasic Implant in the 
Knee Joint 
18-55 yrs 24 mths 
Agili-C Bi-
phasic 
implantation and 
mini-arthrotomy 
or arthroscopy 
NCT01347892 2011-2019 
DeNovo NT Ankle LDC 
Study 
≥ 18 yrs 5 yrs 
DeNovo NT 
Natural Tissue 
Grafting 
NCT01747681 2012-2013 
Results at 10 to 14 Years 
After Microfracture in the 
Knee 
18-80 yrs 10 yrs Microfracture 
NCT01554878 2012-2014 
Observational Study on 
the Treatment of Knee 
OC Lesions of Grade III-
IV 
30-60 yrs 12 mths 
Knee surgery 
 
NCT01920373 
(cancelled) 
2013 
 
Phase 1 
Platelet-Rich Plasma vs 
Corticosteroid Injection 
as Treatment for 
Degenerative Pathology 
of the 
Temporomandibular Joint 
n.d. 6 mths 
Corticosteroid 
and platelet rich 
plasma injection  
 
NCT01799876 2013-2015 
Use of Cell Therapy to 
Enhance Arthroscopic 
Knee Cartilage Surgery 
18-68 yrs 12 mths 
Autologous cell 
and standard 
microfracture 
arthroscopic 
surgery 
NCT02005861 
2013-2016 
 
Phase 3 
"One-step" BM 
Mononuclear Cell 
Transplantation in Talar 
OC Lesions 
15-50 yrs 
 
24 mths 
BM derived 
cells 
transplantation 
on collagen 
scaffold 
NCT02011295 
2013-2017 
 
Phase 4 
BM Aspirate Concentrate 
Supplementation for OC 
Lesions 
18- 95 yrs 24 mths 
Ankle 
arthroscopy with 
debridement and 
microfracture  
 
n.d.: not defined 
 
 
5.6 COMMERCIAL PRODUCTS 
 
The process of commercialization of the scaffolds for implantation involves multiple stages of 
R&D replications before reaching the final approval from the governing bodies. R&D stages 
ensure safety and efficacy of the implants, which involve the production of medical grade 
scaffolds followed by animal testing under regulatory approved conditions. Scaffolds for bone 
tissue engineering are classified as biomedical devices under Class II- Medium Risk (127). For 
bone regeneration there are no tissue engineered approaches fully approved for clinical 
application. Instead, just engineered materials/scaffolds already regulatory approved are arriving 
in the clinic as bone grafts (without the combination of cells), such as Infuse
®
 Bone Graft 
(Medtronic Sofamor Danek) used for fusion of spinal cage, Osigraft (Stryker Biotech) for 
long bone non-unions applications, and Grafton
®
 Orthoblend (OsteoTech) as a bone void filler 
for small and large defects, have been successfully reported. Despite their efficacy in bone 
regeneration, clinical translation of scaffold-based bone therapies is limited to small defects due 
to insufficient mechanical integrity.  
FDA approved scaffolds for craniofacial applications, such as Osteoplug and Osteomesh, are so 
far produced by Osteopore
TM
. These scaffolds are composed of filaments of three-dimensional 
inter-woven PCL polymer. They have higher mechanical strength and its architecture minimizes 
potential injuries to the exposed brain through the burr holes. Long-term clinical trials revealed 
significant bone regeneration with adequate resorption rate and no adverse reactions (128).  
Concerning cartilage tissue engineering, MACI is the better established technique for cartilage 
repair and the only FDA approved cell-based regenerative approach. Named CARTICEL, uses 
patient own cartilage cells (chondrocytes) to treat and repair the articular cartilage damage in the 
knee (28). However, nowadays there are some acellular approaches entering into the market. In 
fact, some of the products present in table 5.2 are already being commercialized. 
Bilayered or multilayered scaffolds, consisting of bone- and cartilage-like layers, seem to be the 
most promising strategy to achieve OC lesion regeneration (129). Some studies have revealed 
promising results conjugating multilayer structures for OC regeneration and some acellular 
products are already being commercialized (101, 130). Among these few structures already in 
clinic, only three were reported in literature (Figure 5.7) one is a bilayer PLGA-calcium-sulphate 
co-polymer porous structure (Figure 5.7 a) (131). The second OC scaffold is a nanostructured 
biomimetic HA-collagen scaffold with a porous 2D trilayer composite structure, mimicking the 
whole OC anatomy (Figure 5.7 b) (130). The Kensey Nash Cartilage Repair Device (CRD) is a 
biphasic (Figure 5.7 c), bioresorbable scaffold intended to be implanted at the site of a focal 
articular cartilage lesion or OCD in the knee (132). This CRD technology utilizes a biphasic 
design that contains two discrete layers. The chondral phase consists of a unique bovine collagen 
type I matrix. The subchondral phase consists of β-TCP mineral suspended within a porous 
bioresorbable synthetic polymer scaffold (132). Other OC scaffolds are still under preclinical 
investigation (130). 
 
 
(Insert Figure 7) 
 
 
 
 
5.7 CONCLUSIONS AND FUTURE DIRECTIONS 
 
It is known that tissue engineered technologies can take up to 20 years for reaching the market, 
and despite progress in many fields, this timeframe has yet to be shorten. Accordingly, tissue 
engineering, which has officially given its first steps during the late eighties, has not supplied 
many products to the bedside. Cell therapy strategies, as well as its first allogeneic stem cell 
therapy products, have been successfully applied for only few applications. Therefore, it is clear 
that, in spite of recent advances, tissue engineering has much to deliver in respect to combined 
products comprising biomaterials, growth factors/bioactive molecules and cells (differentiated or 
undifferentiated). Innovative strategies, such as the ones aforementioned, present out of the box 
solutions for some of the present challenges in the field, and may constitute major breakthroughs 
in future in order to finally catalyze the translation of tissue engineered products from bench to 
bedside. 
Using a product comprising a biomaterial seeded with cells from the own patient is appealing. 
Despite this, the culture conditions, mechanical stimuli, GFs cocktails and environment 
conditions (as oxygen tension and tonicity) have to be better understood, correlated and 
optimized for the ideal regenerative product to be obtained. 
In a static cell culture system the environment is constantly changing due to accumulation of 
metabolites, nutrient consumption in the culture medium and the consequent change in pH. This 
situation is clearly not representative of the in vivo state, in which cells are maintained in 
equilibrium between the constant supply of nutrients and removal of products through the 
cellular secretory mechanism. Moreover the metabolic requirements of a complex 3D 
environment are substantially larger than the necessary to maintain cell monolayers. To 
overcome these difficulties several different bioreactor systems have been developed. A 
bioreactor can be described as a device or dynamic system for culturing cells or tissues under 
controlled conditions either biochemical or mechanically. Different bioreactors have been 
reported in the literature, including mixed flasks, rotating vessels, perfused cartridges, and 
bioreactors with different mechanical stimulation. For cartilage or bone tissue engineering 
separately there are some more options to improve the tissue maturation, as bioreactors with 
pneumatic compression, hypoxia chambers and flow perfusion bioreactors. The main limitation 
of the current bioreactors for OC tissue engineering is that the newly formed tissue(s) is not 
homogeneously distributed within the constructs. Furthermore, there are just one bioreactor 
adapted for bilayered scaffolds (OC-related applications) that support different culture medium 
for each layer of the bilayered constructs, allowing inducing rotatory stimulus, compression and 
vertical movement to avoid cell sedimentation and undesired tissue malformation, at the same 
time. Therefore, the developments in OC tissue regeneration and OC products in particular will 
be greatly dictated by the future developments in bioreactors and dynamic culture 
techniques/systems. 
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FIGURE CAPTIONS 
 
 
FIGURE 5.1   Bone and cartilage micro- and nano-sized cylinder formation. Reprinted from Ref. 
(7), with permission.  
 
 
FIGURE 5.2  Representative images as summary of cartilage regeneration techniques: (a) full-
thickness focal chondral lesion; (b) debridement; (c) microfracture; (d) ACI; and (e) MACI. 
Reprinted from Ref. (17), with permission. 
 
 
FIGURE 5.3   HAp scaffolds: a) macroscopic image; b) and c) microstructure. Reprinted from 
Ref. (78), with permission. 
 
 
FIGURE 5.4   SF/nano-HAp scaffolds: a) macroscopic image (scale bar: 3 mm); b1), b2) and 
b3) microstructure (scale bar: 500 nm). Reprinted from Ref. (87), with permission.  
 
 
FIGURE 5.5   Microstructure of the hydrogel with 15% of nanosized HAp concentration. Arrow 
indicates the polymer-nanoparticle aggregates (scale bar 2 μm). Adapted from Ref. (95), with 
permission. 
 
 
FIGURE 5.6   Microstructures of the composite fibrous scaffold Gel/CaP/PCL: a) gelatin side 
and b) PCL side. Scale bar 10 um. Adapted from Ref. (99), with permission. 
 
 
FIGURE 5.7 Scaffolds commercialized for OC regeneration: (a) TruFit CB® implants in 
increasing diameters (7, 9 and 11 mm) (Reprinted from Ref. (133) with permission); (b) 
Maioregen® scaffold presenting three different gradient layers (Reprinted from Ref. (132) with 
permission); and (c) CRD technology utilizes a biphasic design that contains two discrete layers 
(Reprinted from Ref. (134), with permission). 
 
 
